SGLT2-Inhibitors for Treatment of NAFLD
Great Hall A
Level 1, Ernest N. Morial Convention Center
Q&A with Mohammad S. Kuchay, MD, DM
Medanta, The Medicity Hospital
What is your presentation about?
My presentation is about the role of SGLT2-inhibitors in the treatment of nonalcoholic fatty liver disease (NAFLD).
What makes this topic important in 2022?
NAFLD is a common condition in people with diabetes. NAFLD progresses to complications, such as liver fibrosis and cirrhosis in a significant proportion of these individuals. Physicians should be aware of this condition, so that they can recognise this condition on time, and provide strategies to reverse the condition or mitigate its long-term consequences.
How did you become involved with this area of diabetes research or care?
I got interested in this area around 2016. I examined the research question of what the effect of the SGLT2-inhibitor, empagliflozin, on liver enzymes and liver fat was in patients with type 2 diabetes and NAFLD. The study, E-LIFT trial, published in Diabetes Care, was first to demonstrate that empagliflozin reduces liver fat and improves liver enzymes in these patients.
What are you most looking forward to at the 82nd Scientific Sessions?
I am excited to be attending the ADA annual meeting. It is a scientific and research feast. I want to meet other researchers in this field and want to collaborate with them. I want to further refine my skill and knowledge.